Advertisement

Topics

Cempra Gets Easier Path To CRL Response, But Who Will Fund The Study?

14:05 EDT 9 Aug 2017 | SCRIP

The biotech now only needs to investigate liver toxicity in 6,000 patients – down from 9,000 – to refile its...

      

Related Stories

 

Original Article: Cempra Gets Easier Path To CRL Response, But Who Will Fund The Study?

NEXT ARTICLE

More From BioPortfolio on "Cempra Gets Easier Path To CRL Response, But Who Will Fund The Study?"

Quick Search
Advertisement
 

Relevant Topics

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

Hepatology
Hepatology is the study of liver, gallbladder, biliary tree, and pancreas, and diseases associated with them. This includes viral hepatitis, alcohol damage, cirrhosis and cancer. As modern lifestyles change, with alcoholism and cancer becoming more promi...